€26.67
Your prediction
Arrowhead Pharmaceuticals Inc. Stock
Pros and Cons of Arrowhead Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Arrowhead Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc. | -0.110% | 2.498% | 8.459% | -15.708% | -5.291% | -52.813% | 2.028% |
| Ironwood Pharmaceuticals | 0.800% | 5.882% | 10.526% | -35.052% | -38.235% | -43.243% | - |
| Novocure Ltd | -2.160% | 1.685% | 1.207% | -52.683% | 20.455% | -88.956% | - |
| Iovance Biotherapeutics Inc. | -3.130% | 16.416% | 12.335% | 34.067% | 9.170% | -54.804% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Arrowhead Pharma (ARWR) is a company within the Biotechnology and Medical Research industry, focusing on the development of therapeutic solutions. At first glance, the financials of the company seem to indicate some potential areas of concern, alongside some positive achievements. To gain a deeper understanding of the company's financial health and make an informed assessment, it is essential to delve into the details and identify the pros and cons of its financial performance.
Growing Revenue: Arrowhead Pharma has demonstrated a consistent growth in revenue over the years. In 2020, the total revenue was $87,992,066, which increased to $138,287,000 in 2021 and $243,231,000 in 2022. A growing revenue stream reflects positively on the company's business strategies and market presence.
Robust Research & Development (R&D) Investments: The company has consistently increased its investment in R&D, highlighting its commitment to innovation, a crucial factor for success in the biotechnology and medical research industry. In 2020, R&D expenses were $128,874,979, followed by an increase to $206,342,000 in 2021 and further to $297,307,000 in 2022.
Comments
